STOP-AUST: The Spot sign and Tranexamic acid On Preventing ICH growth – AUStralasia Trial

Registry ID

EUCTR2013-001262-42

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

National Stroke Research Institute

Start date

2013-12-10

Completion date

2019-11-13

Last update

2026-08-16

Conditions

• Intracerebral Haemorrhage

Summary

To test the hypothesis that ICH patients selected with CTA “spot sign” will have lower rates of haematoma growth when treated with intravenous tranexamic acid within 4.5 hours of stroke onset, compared to placebo.

Locations

• , , Finland

Related clinical trials

• NICardipine for Fast Achievement of Systolic BP Targets in ICH
• International Care Bundle Evaluation in Cerebral Hemorrhage Research
• Testing the Effectiveness of a Novel Intervention to Improve Medication Adherence in Stroke Survivors
• Comparison of Blended Care Outpatient Neurorehabilitation With Traditional Outpatient Neurorehabilitation
• Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability
• AI-assisted Transcranial Duplex Sonography for Early Detection of Intracerebral Haemorrhage: HYPER-AI-SCAN

View on source registry